3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
3
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
CNS
1
Conditions
Breast Neoplasms
2
Neoplasms by Site
1
Neoplasms
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Breast Diseases
1
Brain Neoplasms
1
Brain Diseases
1
Interventions
pembrolizumab
302
Carboplatin
230
Cisplatin
159
Paclitaxel
153
Gemcitabine
153
Pemetrexed
122
Bevacizumab
121
Docetaxel
105
durvalumab
83
Oxaliplatin
82
Nivolumab
82
Dexamethasone
80
atezolizumab
79
Fluorouracil
79
Cyclophosphamide
79
130-nm albumin-bound paclitaxel
74
Fulvestrant
72
Capecitabine
67
Injections
66
Cetuximab
64
Leucovorin
63
Rituximab
57
fludarabine
52
Lenalidomide
51
venetoclax
47
Prednisone
45
Irinotecan
42
enzalutamide
41
Letrozole
41
tislelizumab
38
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
RAD1901
×
90 days
×
Clear all
NCT05386108
2026-06-04
ELECTRA
Stemline Therapeutics, Inc.
Phase 1/2
Recruiting
73 enrolled
NCT05963997
2026-03-23
SUMIT-ELA
Carrick Therapeutics Limited
Phase 1/2
Completed
49 enrolled